U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266441) titled 'A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma' on Nov. 25.
Brief Summary: The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Study Start Date: March 17, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: JNJ-79635322
JNJ-79...